Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

@inproceedings{Guo2010SubsequentCR,
  title={Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer},
  author={Ren-hua Guo and Xiaofen Chen and Tongshan Wang and Zhi-yuan Zhang and Jin Sun and Yongqian Shu},
  booktitle={BMC Cancer},
  year={2010}
}
Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib. Here, we report the successful treatment with alternating chemotherapy and TKIs of two cases of advanced NSCLC who developed resistance to TKI. Two patients with advanced or metastatic NSCLC were treated with palliative chemotherapy followed by erlotinib/gefitinib. When TKI therapy failed, two… CONTINUE READING
6 Citations
25 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 25 references

followed by chemotherapy

  • GJ Riely, MG Kris, +8 authors VA Miller
  • Lung Cancer
  • 2010

Similar Papers

Loading similar papers…